When drug companies promote their products, they often emphasize the benefits, but it's crucial to critically assess these claims. Instead of taking marketing at face value, dig deeper into independent research from unbiased sources like medical journals or regulatory agencies. In this episode of the Optispan Podcast, Matt highlights a press release promoting a senolytic/NAD booster for dogs, claiming it can reverse age-related decline. He reviews the claims, the uncertainty around the product’s contents, and whether it should be available to pet owners, setting the stage for a deeper dive into the research in Part II.

Key Points:

This episode delves into a press release claiming a senolytic/NAD booster reverses age-related decline in dogs. Matt questions the claims, highlights unclear product details, and urges independent research to avoid being misled by marketing. 

• Critique of Press Release Claims: The podcast questions a press release from Animal Biosciences that claims a supplement can reverse ageing in dogs, highlighting the lack of solid evidence to support these assertions.
• Understanding Preprints: It explains the nature of preprints, which are early versions of research papers that haven’t undergone peer review, urging caution when such studies are used for marketing purposes.
• Product Composition Concerns: The host discusses the unclear details about the ingredients in the supplement, specifically the NAD booster and senolytic components, noting a lack of data supporting their efficacy in dogs.
• Scientific Skepticism on Benefits: While acknowledging the potential for healthspan improvements through senolytics and NAD boosters, the podcast emphasizes the mixed results in scientific studies and the need for more evidence in dogs.
• Caution for Pet Owners: The episode advises pet owners to be cautious about using unproven supplements, as there are significant unanswered questions regarding the product’s safety, efficacy, and potential side effects.